Compounds, formulations, and methods for ameliorating...

Details Compounds, formulations, and methods for ameliorating... Compounds, formulations, and methods for ameliorating...

2006-06-08

2010-11-23

Fubara, Blessing M (Department: 1613)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S249000, C514S651000, C424S401000

Reexamination Certificate

active

07838563

ABSTRACT:
Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an α-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.

REFERENCES:
patent: 3278447 (1966-10-01), McNicholas
patent: 3560501 (1971-02-01), Walker
patent: 3594380 (1971-07-01), Sulkowski
patent: 3723432 (1973-03-01), Ott
patent: 3736297 (1973-05-01), Bracke
patent: 3740442 (1973-06-01), Ott
patent: 3890319 (1975-06-01), Danielewicz et al.
patent: 4029792 (1977-06-01), Danielewicz et al.
patent: 4164570 (1979-08-01), Clough et al.
patent: 4201211 (1980-05-01), Chandrasekaran et al.
patent: 4285967 (1981-08-01), Gubernick et al.
patent: 5021416 (1991-06-01), Gluchowski
patent: 5077292 (1991-12-01), Gluchowski
patent: 5112822 (1992-05-01), Gluchowski
patent: 5130441 (1992-07-01), Gluchowski
patent: 5198442 (1993-03-01), Gluchowski
patent: 5204347 (1993-04-01), Gluchowski
patent: 5237072 (1993-08-01), Gluchowski
patent: 5300504 (1994-04-01), Gluchowski
patent: 5326763 (1994-07-01), Gluchowski et al.
patent: 5373010 (1994-12-01), Gluchowski et al.
patent: 5418234 (1995-05-01), Gluchowski et al.
patent: 5424078 (1995-06-01), Dziabo et al.
patent: 5442053 (1995-08-01), della Valle et al.
patent: 5552403 (1996-09-01), Burke et al.
patent: 5561132 (1996-10-01), Burke et al.
patent: 5587376 (1996-12-01), Burke et al.
patent: 5693646 (1997-12-01), Jones et al.
patent: 5696127 (1997-12-01), Jones et al.
patent: 5703077 (1997-12-01), Burke et al.
patent: 5714486 (1998-02-01), Burke et al.
patent: 5720962 (1998-02-01), Ivy et al.
patent: 5721237 (1998-02-01), Myers et al.
patent: 5736165 (1998-04-01), Ripley et al.
patent: 5753637 (1998-05-01), Fried
patent: 5756503 (1998-05-01), Burke et al.
patent: 5773440 (1998-06-01), Burke et al.
patent: 6117871 (2000-09-01), Maurer et al.
patent: 6117877 (2000-09-01), Fogel
patent: 6194415 (2001-02-01), Wheeler et al.
patent: 6248741 (2001-06-01), Wheeler et al.
patent: 6284765 (2001-09-01), Caffrey
patent: 6323204 (2001-11-01), Burke et al.
patent: 6387383 (2002-05-01), Dow et al.
patent: 6441047 (2002-08-01), DeSantis, Jr.
patent: 6444681 (2002-09-01), Flavahan et al.
patent: 6465464 (2002-10-01), Wheeler et al.
patent: 6468989 (2002-10-01), Chang et al.
patent: 6517847 (2003-02-01), Dow et al.
patent: 6534048 (2003-03-01), Borgman
patent: 7014858 (2006-03-01), Ashley
patent: 7439241 (2008-10-01), DeJovin et al.
patent: 2002/0197300 (2002-12-01), Schultz et al.
patent: 2003/0068343 (2003-04-01), Muizzuddin et al.
patent: 2003/0077301 (2003-04-01), Maibach et al.
patent: 2003/0087962 (2003-05-01), Demopulos et al.
patent: 2004/0092482 (2004-05-01), Gupta
patent: 2004/0156873 (2004-08-01), Gupta
patent: 2004/0220259 (2004-11-01), Yu et al.
patent: 2004/0242588 (2004-12-01), Dejovin et al.
patent: 2004/0254252 (2004-12-01), Engles et al.
patent: 2004/0266776 (2004-12-01), Gil et al.
patent: 2005/0020600 (2005-01-01), Scherer
patent: 2005/0165079 (2005-07-01), Shanler et al.
patent: 1381979 (1975-01-01), None
patent: WO 96/25163 (1996-08-01), None
patent: WO 98/36730 (1998-08-01), None
patent: WO 00/76502 (2000-12-01), None
Scruggs, Jennifer T., et al., The Teardrop Sign: a Rare Dermatological Reaction to Brimonidine,Br J Ophthalmol, Jun. 2000, V. 84, pp. 671-672.
Sakakibara, R. et al., Treatment of Primary Erythromelalgia with Cyproheptadine,Journal of the Autonomic Nervous System, V. 58, Nos. 1+2, Apr. 20, 1996, pp. 121-122.
Jeyara, J., Selvi C., et al., Cooling Evokes Redistribution of α2c-Adrenoceptors from Golgi to Plasma Membrane in Transfected Human Embryonic Kidney 293 Cells,Molecular Pharmacology, V. 60, No. 6, Dec. 2001, pp. 1195-1200.
Fuchs, Perry N., et al., Heat, but not Mechanical Hyperalgesia, following Adrenergic Injections in Normal Human Skin,Pain, V. 90, Nos. 1-2, Feb. 1, 2001, pp. 15-23.
Morrison, Shaun F., et al., Adrenergic Modulation of a Spinal Sympathetic Reflex in the Rat,J. Pharmacol. Experim. Therap., V. 273, No. 1, 1995, pp. 380-385.
Yaksh, Tony Y., et al., Reversal of Nerve Ligation-Induced Allodynia by SpinalAlpha-2 Adrenoceptor Agonists,J. Pharmacol. Experim. Therap., V. 272, No. 1, 1995, pp. 207-214.
Waldron, C.J., et al., Relative Contribution of Different Vascular Beds to the Pressor Effects of α-Adrenoceptor Agonists and Vasopressin in Pithed Rats: Radioactive Microsphere Determination,J. Auton. Phannac., 1985, V. 5, pp. 333-338.
Bockman et al. “Binding and Functional Characterization of Alpha-2-Adrenergic Receptor Subtypes on Pig Vascular Endothelium, ” J. Phamacol. Exp. Therapeutics, 1993, vol. 267, pp. 1126-1133.
Burke and Schwartz, “Preclinical Evaluation of Brimonidine,” Survey of Ophthalmology, 1996, vol. 41, pp. S9-S18.
Chein et al., “Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes,” Current Eye Research, 1990, vol. 9, No. 11, pp. 1051-1059.
Chotani et al. “Silent αsc-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries,” Am. J. Physiol. Heart Circ. Physiol., 2000, vol. 278, pp. H1075-H1083.
Freedman and Blacker, “Estrogen raises the sweating threshold in postmenopausal woman with hot flashes,” Fertility and Sterility, 2002, vol. 77, No. 3, pp. 487-490.
Guarrera et al., “Flushing in Rosacea: A Possible Mechanism,” Arch. Dermatol. Res. 1982, vol. 272, pp. 311-316.
Nakamura and Ferreira, “Peripheral analgesic action of clonidine: mediation by release of endogenous enkephlin-like substances,” European Journal of Pharmacology, 1988, vol. 146, pp. 223-228.
Nielsen et al., “Postjunctional α2-aradrenoceptors mediate vasoconstriction in human subcutaneous resistance vessels,” Br. J. Pharrnacol., 1989, vol. 97, pp. 829-834.
Walters, “Development and Use of Brimonidine in Treating Acute and Chronic Elevations of Intraocular Pressure: A Review of Safety, Efficacy, Dose Response, and Dosing Studies:” Survey of Ophthalmology, 1996, vol. 41, pp. S19-S26.
Wilkin, “Effect of Subdepressor Clonidine on Flushing Reactions in Rosacea:” Arch. Dermatol., 1983, vol. 119, pp. 211-214.
Wilkin, “Why is flushing limited to a mostly facial cutaneous distribution? ” J. Am. Acad. Dermatol., 1988, vol. 19, pp. 309-313.
Wymenga, A.N. et al., Management of Hot Flushes in Breast Cancer Patients, Acta Ocologica, 2002, vol. 41, No. 3, pp. 269-275.
Rebora, Alfredo, “The Management of Rosacea”, Am. J. Clin. Dermatol. 2002; 3 (7); pp. 489-496.

Affiliated with

Also associated with

Rating

Compounds, formulations, and methods for ameliorating... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds, formulations, and methods for ameliorating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, formulations, and methods for ameliorating... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4244297